Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > We will never know

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Jan 27, 2021 7:22pm

148 Views

Post# 32404332

RE:RE:We will never know

I'm a long, and I am really hoping for the best.

but....I fear seeing a report that CEO Dan sold more stock, and saying "well my wife wants me to put in a trust."

Dan said things would be picking up and moving in January, Dan went on this parade to encourage US investors....and we are going backwards.

Hope it's all computer trading, but I am always skeptical!

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload